Stryker (NYSE:SYK) Price Target Raised to $340.00 at Truist Financial

Stryker (NYSE:SYK) had its target price lifted by Truist Financial from $330.00 to $340.00 in a report issued on Friday morning,Benzinga reports. The firm currently has a hold rating on the medical technology company’s stock.

Other equities research analysts have also issued research reports about the company. Citigroup reduced their price target on Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. Canaccord Genuity Group lowered their price objective on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research report on Friday, May 1st. BTIG Research cut their price objective on Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a research note on Friday. Argus set a $370.00 target price on Stryker in a report on Thursday, July 9th. Finally, Wells Fargo & Company decreased their target price on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and an average price target of $387.88.

Stryker Price Performance

SYK stock opened at $326.41 on Friday. The company has a market capitalization of $125.13 billion, a P/E ratio of 33.82, a PEG ratio of 2.23 and a beta of 0.77. The company has a fifty day moving average price of $317.28 and a 200-day moving average price of $334.92. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. Stryker has a 52-week low of $281.00 and a 52-week high of $401.99.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 24.06%. Stryker’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts expect that Stryker will post 14.99 EPS for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date was Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Insider Transactions at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 323,264 shares of company stock valued at $100,659,489. Corporate insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On Stryker

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Stryker by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock worth $11,917,396,000 after buying an additional 133,892 shares during the period. State Street Corp lifted its position in shares of Stryker by 2.1% during the 4th quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock valued at $5,374,731,000 after acquiring an additional 311,507 shares during the period. Geode Capital Management LLC lifted its position in shares of Stryker by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock valued at $2,636,238,000 after acquiring an additional 69,851 shares during the period. Wellington Management Group LLP boosted its stake in Stryker by 22.6% during the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after acquiring an additional 1,198,665 shares in the last quarter. Finally, Norges Bank bought a new position in Stryker during the fourth quarter worth $1,822,272,000. 77.09% of the stock is currently owned by institutional investors.

Trending Headlines about Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker reported second-quarter revenue of $6.59 billion, up 9.4% year over year, while adjusted EPS of $3.69 exceeded consensus estimates. Organic sales growth reached 9%, supported by strong demand for orthopedic, spinal and other medical devices. Stryker beats quarterly estimates on strong demand for medical devices
• Positive Sentiment: Management said it has regained momentum following the cyber disruption and resumed share repurchases. Its full-year guidance calls for 8.3% to 9.3% organic sales growth and adjusted EPS of $14.95 to $15.10. Stryker expects 2026 organic sales growth and adjusted EPS
• Positive Sentiment: JPMorgan maintained an “overweight” rating, although it reduced its price target to $350. Truist raised its target to $340 while retaining a “hold” rating, and BTIG continues to rate the shares “buy.”
• Neutral Sentiment: The updated guidance was narrower but remained broadly close to prior expectations and analyst forecasts. This suggests operational stability, but not a major upside revision that could drive a stronger investor reaction.
• Neutral Sentiment: Analyst opinion remains generally constructive, with no recent sell ratings cited and a six-month median price target of $385, though target reductions indicate some caution regarding valuation or near-term upside.
• Negative Sentiment: The main pressure on SYK appears to be an expectations reset: despite the earnings beat, investors had anticipated a more substantial increase to full-year guidance after the cyberattack recovery. SYK falls despite Q2 earnings beat
• Negative Sentiment: Reported insider activity has been heavily weighted toward selling, with no purchases and substantial sales over the past six months. This may add to investor concerns about valuation and management confidence, although the trades do not necessarily reflect current operating performance.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.